Richard Moore MD
Gynecologic Oncology
Professor, Obstetrics and Gynecology, Gynecologic Oncology, Wilmot Cancer Institute, University of Rochester Medical Center
Join to View Full Profile
125 Lattimore RdSte 258Rochester, NY 14620
Phone+1 585-442-8020
Fax+1 585-442-8039
Dr. Moore is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- I am Board Certified in Gynecologic Oncology and Obstetrics and Gynecology. I am a Fellow of the ACOG and a Fellow American College of Surgeons
Education & Training
Women and Infants Hospital of Rhode Island/Brown UniversityFellowship, Gynecologic Oncology, 1999 - 2002
Eastern Virginia Medical SchoolResidency, Obstetrics and Gynecology, 1993 - 1997
University of AlbertaClass of 1993
Certifications & Licensure
NY State Medical License 2015 - 2026
MA State Medical License 2001 - 2016
RI State Medical License 1999 - 2016
CT State Medical License 2002 - 2015
NC State Medical License 1997 - 2003
VA State Medical License 1996 - 2002
American Board of Obstetrics and Gynecology Obstetrics & Gynecology- American Board of Obstetrics and Gynecology Gynecologic Oncology
Awards, Honors, & Recognition
- Fellow (FACS) American College of Surgeons
- Fellow (FACOG) American Congress of Obstetricians and Gynecologists
Clinical Trials
- Ovarian Cancer Risk Estimation in Patients With Pelvic Mass Start of enrollment: 2009 Oct 01
- Evaluation of Multiple Protein and Molecular Biomarkers to Estimate Risk of Cancer in Gynecology Patients Presenting With a Pelvic Mass. Start of enrollment: 2016 Jun 30
- EP0057 in Combination With Olaparib in Advanced Ovarian Cancer Start of enrollment: 2020 Dec 14
Roles: Contact
Publications & Presentations
PubMed
- Mechanism of Inhibition of the MeTC7 Ligand That Covalently Binds to VDR To Reduce PD-L1 Expression.Jérôme Castel, Carole Peluso-Iltis, Angelique Sanchez Dafun, Aurora Silvestri, Judit Osz
Journal of Medicinal Chemistry. 2025-11-13 - PSP-0119: Targeted IRAK4 Degradation as a Novel Therapeutic Strategy for FLT3-Mutant AML.Negar Khazan, Cameron Wa Snyder, Chandhana Ravi, Elizabeth Lamere, Niloy A Singh
Biorxiv. 2025-10-02 - The utility of the novel biomarker HE4 for monitoring epithelial ovarian cancer during PARP inhibitor treatment.Alexandra Morell, Anne Stoklosa, Alexandra Blackman, Youngeun Armbuster, Rachael Rowswell-Turner
International Journal of Gynecological Cancer. 2025-09-27
Press Mentions
Targeted Treatment for Ovarian Cancer DiscoveredFebruary 19th, 2014- FDA Clears Biomarker Test for Ovarian CancerSeptember 6th, 2011
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
